Remove 2024 Remove Heart attacks Remove Myocardial Infarction
article thumbnail

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction

DAIC

mtaschetta-millane Wed, 07/10/2024 - 09:02 July 10, 2024 — CellProthera , a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc. , The ProtheraCytes, which are autologous, expanded CD34+ stem cells, were well tolerated with no unexpected serious adverse events reported.

article thumbnail

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. The study enrolled 6,522 people treated for acute myocardial infarction at 451 centers in 22 countries. About 32% had Type 2 diabetes.

article thumbnail

No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1, A Building Block of HDL Cholesterol

DAIC

milla1cf Sat, 04/06/2024 - 18:32 April 6, 2024 — The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at the American College of Cardiology ’s Annual Scientific Session.

article thumbnail

Research Presented at ACC 2024 Found No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1

DAIC

The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at ACC.24, 24, the American College of Cardiology Annual Annual Scientific Session.

article thumbnail

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,

article thumbnail

Questioning Beta-Blocker Interruption After Heart Attack

CardiacWire

Results from the ABYSS trial surprised many at ESC 2024, finding that patients who continue beta-blocker therapy after heart attacks have better long-term outcomes than patients who stop taking the drugs, and they don’t experience the quality of life downsides that some might expect.

article thumbnail

Beta Blockers May Not Benefit Many Heart Attack Survivors

DAIC

The findings call into question the routine use of beta blockers for all patients following a heart attack, which have stood as a mainstay of care for decades. Approximately 50% of heart attack survivors do not experience heart failure. Over a median follow-up period of 3.5